Results 41 to 50 of about 5,245,251 (341)

The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials

Platelets, 2020
Cytochrome P450 (CYP) 2C19 genotype is closely associated with the metabolism and efficacy of clopidogrel, thereby having an important impact on clinical outcomes of patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary ...
Si-Qi Lyu, Yan-Min Yang, Jun Zhu, Juan Wang, Shuang Wu, Han Zhang, Xing-Hui Shao, Jia-Meng Ren   +7 more
doaj   +1 more source

A hopeful therapy for Niemann-Pick C diseases [PDF]

, 2017
Not abstract ...
Erickson, Robert P., Fiorenza, Maria Teresa   +1 more
core   +1 more source

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. [PDF]

, 2020
Background Reducing major bleeding events is a challenge when managing anticoagulation in patients with atrial fibrillation. This study evaluated the impact of modifiable and nonmodifiable bleeding risk factors in patients with atrial fibrillation ...
Amarenco, P, Camm, AJ, Haas, S, Hess, S, Kirchhof, P, Lambelet, M, Turpie, AGG, van Eickels, M, XANTUS Investigators*   +8 more
core   +2 more sources

Pharmacogenetics of Antiplatelet Therapy.

Annual Review of Pharmacology and Toxicology, 2022
Antiplatelet therapy is used in the treatment of patients with acute coronary syndromes, stroke, and those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used antiplatelet P2Y12 inhibitor in clinical practice.
Matteo Castrichini, Jasmine A. Luzum, N. Pereira   +2 more
semanticscholar   +1 more source

The CLEAR (Considering Leading Experts’ Antithrombotic Regimes around peripheral angioplasty) survey: an international perspective on antiplatelet and anticoagulant practice for peripheral arterial endovascular intervention

CVIR Endovascular, 2019
Background Antiplatelet and anticoagulant therapy are commonly used before, during and after peripheral arterial endovascular intervention. This survey aimed to establish antiplatelet and anticoagulant choice for peripheral arterial endovascular ...
Kitty H. F. Wong, Dave C. Bosanquet, Graeme K. Ambler, Mahim I. Qureshi, Robert J. Hinchliffe, Christopher P. Twine, CLEAR survey collaborators   +6 more
doaj   +1 more source

Outcomes in Antiplatelet‐Associated Intracerebral Hemorrhage in the TICH‐2 Randomized Controlled Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Antiplatelet therapy increases the risk of hematoma expansion in intracerebral hemorrhage (ICH) while the effect on functional outcome is uncertain.
Zhe Kang Law, Michael Desborough, Ian Roberts, Rustam Al‐Shahi Salman, Timothy J. England, David J. Werring, Thompson Robinson, Kailash Krishnan, Robert Dineen, Ann Charlotte Laska, Nils Peters, Juan Jose Egea‐Guerrero, Michal Karlinski, Hanne Christensen, Christine Roffe, Daniel Bereczki, Serefnur Ozturk, Jegan Thanabalan, Rónán Collins, Maia Beridze, Philip M. Bath, Nikola Sprigg   +21 more
doaj   +1 more source

Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]

, 2018
© The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast, AD Michelson, B Labarthe, B Shen, C Patrono, CT Ammollo, D Capodanno, D Gailani, DA Gorog, Diana A. Gorog, DM Coenen, E Álvarez, ER Bates, F Kabirian, F Müller, F Semeraro, G Stephens, H Brogren, HE Speich, HE Speich, HJ Weiss, HJ Weiss, HR Baumgartner, J Zilberman-Rudenko, JD McFadyen, JI Weitz, JM Cosemans, JP Collet, JP Collet, K Hosokawa, K Nagatsuka, KS Sakariassen, L Valerio, LF Brass, M Cattaneo, M Farag, M Humbert, M Larsson, M Li, M Ungerer, MA Bailey, MI Furman, MJ Price, ML Montfoort von, MS Sabatine, P Andre, P Seizer, PA Borne von dem, PP Wadowski, R Hellmuth, R Nergiz-Unal, RA Ajjan, S Goto, S Goto, SA Shaya, SB Larsen, SJ Marciniak, T Heitzer, T Renné, VT Turitto, VT Turitto, WA Schumacher, WS Nesbitt, X Wang, Y Yano, YC Lau, ZM Ruggeri   +66 more
core   +2 more sources

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]

, 2018
© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M, Hirsh J, Ibanez B, Mega JL, Park KW, Suh JW, Valgimigli M   +6 more
core   +3 more sources

Embolic strokes of undetermined source: prevalence and patient features in the ESUS Global Registry [PDF]

, 2016
Background: Recent evidence supports that most non-lacunar cryptogenic strokes are embolic. Accordingly, these strokes have been designated as embolic strokes of undetermined source (ESUS).
Ameriso, Sebastian F, Arauz, Antonio, Berkowitz, Scott D, Bosch, Jackie, Brouns, Raf, Connolly, Stuart J, Coutinho, Jonathan, Cunha, Luis, Gagliardi, Rubens J, Giruparajah, Mohana, Hankey, Graeme J, Hart, Robert G, Kasner, Scott E, Kitagawa, Kazuo, Lavallee, Philippa, Mattina, Katie R, Muir, Keith, O\u2019Donnell, Martin J, Perera, Kanjana S, Pieroni, Alessio, Shamalov, Nikolay, Swaminathan, Balakumar, Vanassche, Thomas, Vastagh, Ildiko, Vermehren, Philipp, Wang, Yongjun, Yoon, Byung-Woo, Yperzeele, Laetitia   +27 more
core   +5 more sources

Association of Antiplatelet Therapy, Including Cilostazol, With Improved Survival in Patients With Moyamoya Disease in a Nationwide Study

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2021
Background Although antiplatelet agents are frequently prescribed in moyamoya disease in routine clinical practice, there are no large‐scale epidemiologic trials or randomized trial evidence to support their use in patients with moyamoya disease. Methods
W. Seo, Jaeyoung Kim, Eun‐Hyeok Choi, Yesel Kim, Jong-Won Chung, J. Saver, O. Bang, Gyeong-Moon Kim   +7 more
semanticscholar   +1 more source